# BioStem Technologies, Inc. (BSEM) — capital_raise/private_placement [announced]
Source: SEC API (secapi.ai) · situation sit_043b47f58d55f2f95df0 · retrieved 2026-08-16T21:03:38.827Z

## Overview
BioStem Technologies, Inc. is a regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, leveraging proprietary BioRetain®, CryoTek®, and SteriTek® processing technologies.

BioStem Technologies, Inc. completed the uplisting of its common stock to the Nasdaq Capital Market on August 7, 2026. The company also closed a $2.5 million private placement with its first institutional investor during the second quarter of 2026.

## Terms
- Deal value: $2.5M

## Key dates
- Announced 2026-08-12

## Timeline
- 2026-08-12 · 8-K (0001193125-26-347211): 8-K - BioStem Technologies, Inc. — *BioStem Technologies, Inc. is a regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, leveraging proprietary BioRetain®, CryoTek®, and SteriTek® processing technologies.* BioStem Technologies, Inc. completed the uplisting of its common stock to the Nasdaq Capital Market on August 7, 2026. The company also closed a $2.5 million private placement with its first institutional investor during the second quarter of 2026.
  https://www.sec.gov/Archives/edgar/data/1658678/0001193125-26-347211.txt

## Citations
- 0001193125-26-347211 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526347211